Nam H-Y, Lee H Y, Park G C
Department of Nuclear Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Clin Otolaryngol. 2016 Aug;41(4):358-64. doi: 10.1111/coa.12520. Epub 2016 Feb 7.
The aim of this study was to investigate the impact of co-existent chronic lymphocytic thyroiditis (CLT) on changes in serum antithyroglobulin antibody (TgAb) and clinical outcome in papillary thyroid carcinoma (PTC) patients with high preoperative serum TgAb.
A retrospective cohort study.
University teaching hospital.
Thirty-seven PTC patients with high preoperative serum TgAb level (≥100 U/mL) were evaluated. All patients underwent total thyroidectomy followed by high-dose I-131 ablation.
Per cent changes of TgAb between pre-treatment and post-treatment, and disease-free survival were calculated.
Twenty-two patients (59.5%) had co-existent CLT, and seven had residual/recurrent tumours. There was a higher proportion of females among the patients with CLT compared to those without CLT (95.5% versus 66.7%; P = 0.0306). There were trends towards more aggressive pathologies, such as tumour size, extrathyroidal extension, surgical margin and lymph node stage, in PTC without CLT than in that with co-existent CLT. Pre-treatment and post-treatment TgAb were all higher in PTC with co-existent CLT. But, per cent changes of TgAb between pre-treatment and post-treatment were no significant difference between PTC with and without CLT (P < 0.05). Patients with co-existent CLT showed a significantly lower residual/recurrent tumour rate than those without CLT (4.5% versus 40%; P = 0.0113).
Residual/recurrent tumour rate was lower in PTC patients with co-existent CLT than in those without CLT.
本研究旨在探讨并存慢性淋巴细胞性甲状腺炎(CLT)对术前血清抗甲状腺球蛋白抗体(TgAb)水平较高的甲状腺乳头状癌(PTC)患者血清TgAb变化及临床结局的影响。
一项回顾性队列研究。
大学教学医院。
评估了37例术前血清TgAb水平较高(≥100 U/mL)的PTC患者。所有患者均接受了甲状腺全切除术,随后进行大剂量碘-131消融治疗。
计算治疗前和治疗后TgAb的变化百分比以及无病生存率。
22例患者(59.5%)并存CLT,7例有残留/复发性肿瘤。与无CLT的患者相比,CLT患者中女性比例更高(95.5%对66.7%;P = 0.0306)。与并存CLT的PTC相比,无CLT的PTC在肿瘤大小、甲状腺外侵犯、手术切缘和淋巴结分期等更具侵袭性的病理特征方面有增加趋势。并存CLT的PTC患者治疗前和治疗后的TgAb均较高。但是,治疗前和治疗后TgAb的变化百分比在有和无CLT的PTC之间无显著差异(P < 0.05)。并存CLT的患者残留/复发性肿瘤率显著低于无CLT的患者(4.5%对40%;P = 0.0113)。
并存CLT的PTC患者残留/复发性肿瘤率低于无CLT的患者。